Literature DB >> 16044199

R352Q mutation of the DHCR7 gene is common among Japanese Smith-Lemli-Opitz syndrome patients.

Yoshiyuki Matsumoto1, Ken-Ichi Morishima1, Akira Honda2, Shoji Watabe3, Misa Yamamoto3, Masayuki Hara4, Masaki Hasui5, Chikako Saito6, Toshimitsu Takayanagi7, Tsutomu Yamanaka8, Nakamichi Saito9, Hideaki Kudo10, Nobuhiko Okamoto11, Masato Tsukahara3, Shinya Matsuura12.   

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive malformation syndrome characterized by microcephaly, syndactyly of toes, ambiguous genitalia, and mental retardation. The underlying DHCR7 gene has been identified and a wide variety of distinct mutations were reported in USA and European SLOS patients. A significant difference has been suggested in the frequency of SLOS among different ethnic populations. Here, we report mutational analysis of seven Japanese SLOS patients. Five mutations, R352Q, R242H, G303R, X476Q, and S192F, were identified, and R352Q appeared most frequent, since nine out of the 13 mutations of Japanese origin were the same R352Q. These results suggest that R352Q is a predominant founder mutation in Japanese SLOS patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044199     DOI: 10.1007/s10038-005-0267-3

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  18 in total

1.  Smith-Lemli-Opitz syndrome in Japan.

Authors:  M Tsukahara; K Fujisawa; K Yamamoto; M Hasui; C Saito; T Yamamaka; A Honda; M Honda; G S Tint; G Salen; J M Opitz
Journal:  Am J Med Genet       Date:  1998-01-06

2.  A new face for an old syndrome.

Authors:  R I Kelley
Journal:  Am J Med Genet       Date:  1997-01-31

3.  Detection of a common mutation in the RSH or Smith-Lemli-Opitz syndrome by a PCR-RFLP assay: IVS8-G-->C is found in over sixty percent of US propositi.

Authors:  H Yu; G S Tint; G Salen; S B Patel
Journal:  Am J Med Genet       Date:  2000-02-14

4.  Mutational spectrum in the Delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome.

Authors:  M Witsch-Baumgartner; B U Fitzky; M Ogorelkova; H G Kraft; F F Moebius; H Glossmann; U Seedorf; G Gillessen-Kaesbach; G F Hoffmann; P Clayton; R I Kelley; G Utermann
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

5.  Frequency and ethnic distribution of the common DHCR7 mutation in Smith-Lemli-Opitz syndrome.

Authors:  M J Nowaczyk; L M Nakamura; B Eng; F D Porter; J S Waye
Journal:  Am J Med Genet       Date:  2001-09-01

6.  Cholesterol biosynthesis from lanosterol. Molecular cloning, tissue distribution, expression, chromosomal localization, and regulation of rat 7-dehydrocholesterol reductase, a Smith-Lemli-Opitz syndrome-related protein.

Authors:  S H Bae; J N Lee; B U Fitzky; J Seong; Y K Paik
Journal:  J Biol Chem       Date:  1999-05-21       Impact factor: 5.157

7.  Clinical and biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism.

Authors:  C Cunniff; L E Kratz; A Moser; M R Natowicz; R I Kelley
Journal:  Am J Med Genet       Date:  1997-01-31

8.  Markedly increased tissue concentrations of 7-dehydrocholesterol combined with low levels of cholesterol are characteristic of the Smith-Lemli-Opitz syndrome.

Authors:  G S Tint; M Seller; R Hughes-Benzie; A K Batta; S Shefer; D Genest; M Irons; E Elias; G Salen
Journal:  J Lipid Res       Date:  1995-01       Impact factor: 5.922

Review 9.  RSH/SLO ("Smith-Lemli-Opitz") syndrome: historical, genetic, and developmental considerations.

Authors:  J M Opitz
Journal:  Am J Med Genet       Date:  1994-05-01

10.  Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome.

Authors:  C A Wassif; C Maslen; S Kachilele-Linjewile; D Lin; L M Linck; W E Connor; R D Steiner; F D Porter
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

View more
  8 in total

1.  Adrenal function in Smith-Lemli-Opitz syndrome.

Authors:  Simona E Bianconi; Sandra K Conley; Meg F Keil; Ninet Sinaii; Kristina I Rother; Forbes D Porter; Constantine A Stratakis
Journal:  Am J Med Genet A       Date:  2011-10-11       Impact factor: 2.802

2.  Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome.

Authors:  Simona E Bianconi; Joanna L Cross; Christopher A Wassif; Forbes D Porter
Journal:  Expert Opin Orphan Drugs       Date:  2015-03       Impact factor: 0.694

3.  Novel DHCR7 mutation in a case of Smith-Lemli-Opitz syndrome showing 46,XY disorder of sex development.

Authors:  Mayuko Tamura; Tsuyoshi Isojima; Takeshi Kasama; Ryo Mafune; Konomi Shimoda; Hiroki Yasudo; Hiroyuki Tanaka; Chie Takahashi; Akira Oka; Sachiko Kitanaka
Journal:  Hum Genome Var       Date:  2017-05-11

Review 4.  Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review.

Authors:  M R Boland; N P Tatonetti
Journal:  Pharmacogenomics J       Date:  2016-07-12       Impact factor: 3.550

5.  Insufficiency of ciliary cholesterol in hereditary Zellweger syndrome.

Authors:  Tatsuo Miyamoto; Kosuke Hosoba; Takeshi Itabashi; Atsuko H Iwane; Silvia Natsuko Akutsu; Hiroshi Ochiai; Yumiko Saito; Takashi Yamamoto; Shinya Matsuura
Journal:  EMBO J       Date:  2020-05-05       Impact factor: 11.598

6.  Carrier frequency and incidence estimation of Smith-Lemli-Opitz syndrome in East Asian populations by Genome Aggregation Database (gnomAD) based analysis.

Authors:  Jong Eun Park; Taeheon Lee; Kyeongsu Ha; Chang-Seok Ki
Journal:  Orphanet J Rare Dis       Date:  2021-04-09       Impact factor: 4.123

Review 7.  The Intimate Connection Between Lipids and Hedgehog Signaling.

Authors:  Thi D Nguyen; Melissa E Truong; Jeremy F Reiter
Journal:  Front Cell Dev Biol       Date:  2022-06-09

8.  A novel DHCR7 mutation in a Smith-Lemli-Opitz syndrome infant presenting with neonatal cholestasis.

Authors:  Jae Sung Ko; Byung Sam Choi; Jeong Kee Seo; Jee Yeon Shin; Jong Hee Chae; Gyeong Hoon Kang; Ran Lee; Chang-Seok Ki; Jong-Won Kim
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.